Tempus AI Inc
NASDAQ:TEM
ROE
Return on Equity
ROE, or Return on Equity, is a key financial ratio that measures a company's profitability. Specifically, it measures how many dollars of profit are generated for each dollar of shareholder's equity. A higher ROE indicates better financial performance and effective use of capital, making it a valuable metric for investors assessing a company's earning potential.
ROE Across Competitors
| Country | Company | Market Cap | ROE | ||
|---|---|---|---|---|---|
| US |
T
|
Tempus AI Inc
NASDAQ:TEM
|
11.4B USD |
10 743%
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
974.7B USD |
4%
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
152.3B USD |
14%
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
135.4B USD |
7%
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
71.2T KRW |
12%
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
39.6B CHF |
7%
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
31.7B USD |
21%
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
179.6B CNY |
20%
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
24.5B USD |
22%
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
24.2B USD |
-499%
|
|
| FR |
|
Sartorius Stedim Biotech SA
PAR:DIM
|
18.9B EUR |
5%
|
Tempus AI Inc
Glance View
Tempus AI Inc. stands at the forefront of the healthcare technology revolution, focusing its expertise on the convergence of artificial intelligence and big data to transform the way doctors approach precision medicine. Founded by Eric Lefkofsky in 2015, the company’s mission is to harness the power of data, equipping physicians with crucial insights that can propel patient care forward. With its sprawling genomic database, Tempus aggregates clinical and molecular information, which is then meticulously analyzed to provide actionable insights. Physicians receive comprehensive reports, offering tailored therapeutic options and clinical trial opportunities that might otherwise remain undiscovered. Monetization for Tempus hinges on its relationships with various stakeholders in the healthcare ecosystem. It primarily earns revenue through partnerships with pharmaceutical companies, where it assists in drug discovery and development by offering detailed genomic data and analytics. Moreover, Tempus collaborates with research institutes and healthcare providers who rely on its AI-driven platform to enhance clinical decision-making and improve treatment outcomes. By bridging the gap between vast datasets and intricate patient care solutions, Tempus not only facilitates better healthcare practices but also solidifies its role as a vital link in the evolving landscape of modern medicine.
See Also
ROE, or Return on Equity, is a key financial ratio that measures a company's profitability. Specifically, it measures how many dollars of profit are generated for each dollar of shareholder's equity. A higher ROE indicates better financial performance and effective use of capital, making it a valuable metric for investors assessing a company's earning potential.
Based on Tempus AI Inc's most recent financial statements, the company has ROE of 10 742.6%.
You don't have any saved screeners yet